Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 577Triple Negative Breast Neoplasms 125Neoplasm Metastasis 50Breast Neoplasms, Male 28Ovarian Neoplasms 26Neoplasms 26Inflammatory Breast Neoplasms 22Carcinoma, Non-Small-Cell Lung 19Stomach Neoplasms 14Endometrial Neoplasms 11Carcinoma, Ductal, Breast 11Carcinoma, Ovarian Epithelial 10Pancreatic Neoplasms 9Colorectal Neoplasms 9Melanoma 8Lung Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7HER2-positive Breast Cancer 7Squamous Cell Carcinoma of Head and Neck 6Prostatic Neoplasms 6Esophageal Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 4Brain Neoplasms 4Anatomic Stage I Breast Cancer AJCC v8 4Advanced Breast Cancer 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × Paclitaxel × Breast × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡